期刊文献+

作为基因转移载体的乙肝病毒衣壳的制备及其功能的初步鉴定 被引量:3

Construction of a liver targeting gene transfer vector using hepatitis B virus envelope particles and assessment of its function
下载PDF
导出
摘要 目的构建具有肝脏靶向性的乙型肝炎病毒衣壳基因转移载体。方法采用PEG8000病毒浓缩法提取HepG2.2.15细胞上清液中的乙型肝炎病毒,用β-丙内酯法制备乙型肝炎病毒衣壳,用它包裹5.3kb的绿色荧光蛋白质粒以测试其装载能力,并用ELISA法、PCR法、SDS-聚丙烯酰胺凝胶电泳、透射电镜等对它进行定量、定性研究,最后将其转染HepG2细胞,通过荧光显微镜观察绿色荧光蛋白表达情况,通过流式细胞仪检测细胞发光率。结果制备的乙型肝炎病毒衣壳载体保留病毒衣壳的表面蛋白HBsAg+preS1+preS2,无病毒DNA;该载体对绿色荧光蛋白质粒较高装载容量,装载绿色荧光蛋白质粒后在肝癌细胞中有很高的转移效率,并能实现高表达。结论采用PEG8000病毒浓缩法、β-丙内酯法可从HepG2·2·15细胞上清液中制备乙型肝炎病毒衣壳基因转移载体,该载体具有良好的生物学功能。 Objective: To construct a liver targeting gene transfer vector using hepatitis B virus envelope particles. Methods: Hepatitis B viruses were obtained from the supematant of HepG 2.2. I5 cells by a PEG8000 system and were inactivated by β-propiolactone to prepare hepatitis B virus envelope. The hepatitis B virus envelope was used to pack 5.3 kb pIRES2-EGFP to assess their packing ability. Subsequently, the products were studied with ELISA, PCR, SDSPAGE, and electron microscopy. Finally, the product was used to transfect HepG2 cells and the green fluorescent protein (GFP) expression was observed under a fluorescent microscope. The rate of GFP positive cells was determined by flow cytometer. Results : The acquired hepatitis B virus envelope retained the surface protein HBsAg + pre S1 + pre S2, but with no virus DNA. The prepared envelope had high packing ability for GFP and the packed GFP had a high transfection rate in HepG2 cell. Conclusion: Hepatitis B virus envelope has been successfully obtained from the supernatant of HepG 2. 2. 15 cells with a PEG8000 system and β-propiolactone.
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 2006年第5期358-361,共4页 Chinese Journal of Cancer Biotherapy
基金 国家自然科学基金资助项目(No.30100189)
关键词 乙型肝炎病毒 衣壳 肝脏 靶向性 基因转移 Hepatitis B virus, envelope, liver, targeting, gene transfer
  • 相关文献

参考文献11

  • 1Park CW,Park YM,Lee GT,et al.Targeting of therapeutic gene expression to the liver by using liver-type pyruvate kinase proximal promoter and the SV40 viral enhancer active in multiple cell types[J].Biochem Biophys Res Commun,2004,314(1):131-137.
  • 2Park SG,Jeong YJ,Lee YY,et al.Hepatitis B virus neutralizing anti-pre-S1 human antibody fragments from large na ve antibody phage library.Antiviral Res,2005,68(3):109-115.
  • 3Wang L,Kaneko S,Honda M,et al.Approach to establishing a liver targeting gene therapeutic vector using naturally occurring defective hepatitis B viruses devoid of immunogenic T cell epitope[J].Virus Res,2002,85(2):187-197.
  • 4J萨姆布鲁克 EF弗里奇 T曼尼阿蒂斯著 金冬雁 黎孟枫译.分子克隆实验指南[M].北京:科学技术出版社,1999.467.
  • 5薛庆善.体外培养的原理及技术[M].北京:科学出版社,2001.36-40.
  • 6傅继华.病毒学实用实验技术[M].青岛:山东科学技术出版社,2003.102-103.
  • 7Kaneda Y,Nakajima T,Nishikawa T,et al.Hemagglutinating Virus of Japan (HVJ) Envelope Vector as a Versatile Gene Delivery System[J].Mol Ther,2002,6(2):219-226.
  • 8Hilleman MR.Critical overview and outlook:pathogenesis,prevention,and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus[J].Vaccine,2003,21(32):4626-4649.
  • 9Broo K,Wei J,Marshall D,et al.Viral capsid mobility:A dynamic conduit for inactivation[J].Proc Natl Acad Sci USA,2001,98(5):2274-2277.
  • 10Yamada T,Iwabuki H,Kanno T,et al.Physicochemical and immunological characterization of hepatitis B virus envelope particles exclusively consisting of the entire L(pre-S1+pre-S2+S) protein[J].Vaccine,2001,19(23-24):3154-3163.

共引文献15

同被引文献30

  • 1傅继华.病毒学实用实验技术[M].青岛:山东科学技术出版社,2003.102-103.
  • 2Park CW,Park YM,Lee GT,el al.Targeting of therapeutic gene expression to the liver by using liver-type pyruvme kinase proximal promoter and the SV40 viral enhancer active in multiple cell types[J].Biochemi Biophy Res Commun,2004,314(1):131-137.
  • 3Park SG,Jeong YJ,Lee YY,el al.Hepatitis B virus neutralizing anti-pre-S1 hunran antibody fragments from large na? ve antibody phage library[J].Antivir Res,2005,68(3):109-115.
  • 4Wang LQ,Kaneko S,Honda M,el al.Approach to establishing a liver targeting gene therapeutic vector using naturally occurring defective hepatitis B viruses devoid of immunogenic T cell epitope[J].Virus Res.2002,85(2):187-197.
  • 5Kaneda Y,Nakajima T,Nishikawa T,el al.Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system[J].Mol Ther,2002,6(2):219-226.
  • 6Hilleman M R.Critical overview and outlook:pathogenesis,prevention,and treatment of hepatitis and hepatocarcinoma cansed by hepatitis B virus[J],Vaccine,2003,21(32):4626-4649.
  • 7Wells DJ.Gene therapy progress and prospects:electroporation and other physical methods[J].Gene Ther,2004,11(18):1363-1369.
  • 8Nguyen T H,Ferry N.Liver gene therapy:advances and hurdles[J].Gene Ther,2004;11 (Suppl 1):S76-84.
  • 9Park CW,Park YM,Lee GT,et al.Targeting of therapeutic gene expression to the liver by using liver-type pyruvate kinase proximal promoter and the SV40 viral enhancer active in multiple cell types[J].Biochem Biophys Res Commun,2004,314(1):131-137.
  • 10Tharayil VS,Roberts LR.Molecular targets for therapy of hepatitis B virus-induced hepatocellular carcinoma[J].Minerva Gastroenterol Dietol,2006,52(4):387-406.

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部